Ipca Laboratories Limited (IPCALAB.NS)
Makes and sells generic medicines and drug ingredients across India and worldwide
1,774.50-0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+22.4%
The outlook
IPCALAB trades at 1774.5, sitting well above both its 50- and 200-day moving averages and positioned three-quarters of the way up its 52-week range. Analyst consensus leans Buy with strong coverage across 18 firms, though the average price target sits roughly 2% below the current level. The stock carries a trailing P/E of 39.5, reflecting a premium valuation in its current uptrend.
What’s behind the score
Analyst consensusBuy — 1.6 avg of 18 analysts
Price trendAbove its 50- & 200-day averages
52-week range75% of the way from its 52-week low to high
Price targetAvg target -2% vs current price
Analyst price target
~12-month · 18 analysts1,733.50average target-2.3% vs now
Now 1,774.50
Low 1,405.00High 1,980.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$450.20B
52-wk high
1,944.90
52-wk low
1,251.60
50-day avg
1,675.90
200-day avg
1,514.96
Trailing P/E
39.5